FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention relates to use of a derivative containing C-O-P bonds in the form of a controlled-release dosage form for treating patients with renal insufficiency. Invention also includes use of said derivatives together with other active substances, which, in particular, can be selected from a group, comprising a calcimimetic, a vitamin, a phosphate-binding preparation, thiosulphate, bisphosphonate, pyrophosphate, citrate, a diuretic, an antihypertensive agent and an anti-cholesteremia agent.
EFFECT: what is presented is using derivatives containing C-O-P compounds in patients with renal insufficiency.
13 cl, 12 ex, 14 dwg
Title | Year | Author | Number |
---|---|---|---|
INOSITOL PHOSPHATE COMPOUNDS FOR USE IN TREATING, DELAYING PROGRESSION OR PREVENTING CARDIOVASCULAR CALCIFICATION | 2020 |
|
RU2832087C1 |
COMPOSITION, CONTAINING CRYSTALLISATION-INHIBITING SUBSTANCES | 2009 |
|
RU2535094C2 |
INOSITOL PHOSPHATE COMPOUNDS FOR USE IN INCREASING TISSUE PERFUSION | 2020 |
|
RU2838908C2 |
AGENT FOR LOW-TURNOVER METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2491940C1 |
AGENT FOR LOW-METABOLIC BONE DISEASE IN PATIENTS WITH CHRONIC RENAL INSUFFICIENCY | 2012 |
|
RU2485957C1 |
COMPOSITION CONTAINING CRYSTALLIZATION INHIBITORS | 2014 |
|
RU2691060C2 |
NICOTINAMIDE FOR TREATING DISLIPIDEMIA | 2018 |
|
RU2741426C1 |
METHOD FOR REHABILITATION OF PATIENTS WITH RENAL DISEASE | 1999 |
|
RU2177324C2 |
METHOD FOR EXAMINING QUALITY OF EXTRARENAL BLOOD CLEARANCE | 1998 |
|
RU2155074C2 |
METHOD FOR ASSESSING RISK OF CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH CHRONIC KIDNEY DISEASE | 2023 |
|
RU2832086C1 |
Authors
Dates
2020-07-03—Published
2014-03-14—Filed